UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 6

of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'

6
TI
Hepatic vascular lesions associated with dacarbazine treatment.
AU
Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ
SO
Br Med J (Clin Res Ed). 1981;282(6278):1744.
 
Dacarbazine is widely used in the treatment of melanoma. Transient abnormalities of liver function tests are well-recognised side effects of the drug, but acute liver failure due to vascular occlusion in patients receiving single-agent chemotherapy with dacarbazine has been noted only rarely. Two cases are reported in which hepatic vascular lesions developed during treatment with dacarbazine and were confirmed at necropsy. Hepatic vascular occlusion due to treatment with dacarbazine may be less rare than was previously thought. Greater caution may be needed when dacarbazine is prescribed, particularly as an adjuvant agent in stage I and II disease.
AD
PMID